Kailera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for obesity and related conditions. The company develops clinical- and preclinical-stage therapies, with a product pipeline that includes injectable peptides, oral peptides, and oral small molecules. Key programs include KAI-9531, an injectable GLP-1/GIP receptor dual agonist; KAI-7535, an oral small molecule GLP-1 receptor agonist; and KAI-4729, an injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera Therapeutics holds exclusive rights for global development and commercialization of four metabolic disease assets outside of Greater China, with therapies delivered through oral and injectable formulations. The company was founded in 2024 and is based in Waltham, Massachusetts.
| Business Activity | PASS |
| Debt Ratio | N/A |
| Cash Ratio | N/A |
| Receivables Ratio | N/A |
| Revenue Ratio | N/A |
| Overall | INSUFFICIENT DATA |
-0.00
5
1.17
2.32
0.0%
145
| Shares | Cost | Profit to Target | R:R |
|---|---|---|---|
| To Consensus ($42.60, 5 analysts) | |||
| 10 | $219.10 | +$206.90 (94%) | 6.3R |
| 50 | $1,095.50 | +$1,034.50 (94%) | 6.3R |
| 100 | $2,191.00 | +$2,069.00 (94%) | 6.3R |
- No elevated risk flags in current data
A single score combining all analytical layers below. A is strongest, D is weakest.
Is this company financially sound? The Z-Score measures bankruptcy risk. The F-Score measures fundamental strength.
How does this ticker's recent performance compare to the entire universe? Ranked across 1, 3, 6, and 12-month returns.